Pharmaceutical Technology on MSN
Harmony’s cannabidiol drug flops in pivotal Fragile X Syndrome trial
Share price in Harmony tumbled in the wake of the Phase III trial miss, with a route to market for ZYN002 looking bleak.
Zacks Investment Research on MSN
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Shares of Harmony Biosciences Holdings, Inc. HRMY lost 16.56% on Sept. 24 after the company announced the failure of the late-stage registrational RECONNECT study on pipeline candidate ZYN002 in ...
While Harmony management has not disclosed future plans for ZYN002, Jefferies analysts expect the asset to be shelved.
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical ...
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan ...
(RTTNews) - Harmony Biosciences Holdings, Inc. (HRMY) announced Wednesday topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS).
Harmony Biosciences Holdings faces setbacks after a failed trial and sNDA rejection. Click here to find out why HRMY is a Hold.
Shares of Harmony Biosciences Holdings, Inc. HRMY lost 16.56% on Sept. 24 after the company announced the failure of the late-stage registrational RECONNECT study on pipeline candidate ZYN002 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback